Get started
Author

Rong Shi

Observed name: R. Shi
ORCID: 0009-0005-8195-7190
Observed ORCID: 0009-0005-8195-7190
OpenAlex ID: A5091215198
Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.
2023 · Kathleen N. Moore, Dhanusha Sabanathan, et al. · Journal of Clinical Oncology · 19
DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).
2025 · Andrew Ohyama Parsonson, Chintan Gandhi, et al. · Journal of Clinical Oncology · 10
PDF
#430 DB-1303, a HER2-targeting ADC, for patients with advanced/metastatic endometrial cancer: preliminary clinical results from an ongoing phase 1/2a trial (NCT05150691)
2023 · Kathleen Moore, Vicky Makker, et al. · International Journal of Gynecological Cancer · 7
PDF
The Trop-2-targeting antibody drug conjugate DB-1305 has higher antitumor activity and a potentially better safety profile compared with DS-1062
2022 · Y. Zhang, B. Li, et al. · European Journal of Cancer · 5
PDF
Trastuzumab pamirtecan (DB-1303/BNT323) in patients with previously treated HER2-expressing advanced/metastatic endometrial cancer: First global clinical phase 2 data
2026 · Bhavana Pothuri, Debra Richardson, et al. · Gynecologic Oncology · 3
436TiP DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer
2024 · J. O'Shaughnessy, J. Cortés, et al. · Annals of Oncology · 2
PDF
Abstract CT248: First in human trial of DB1305 in patients with advanced malignant solid tumors
2023 · Naoto T. Ueno, Jie Gao, et al. · Cancer Research · 2
DB-1303, a HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising safety profile and anti-tumor efficacy with differentiation from DS-8201a
2022 · S. Lin, Y. Zhang, et al. · European Journal of Cancer · 2
PDF
A global, phase 1/2 study of DB-1311/BNT324 (a novel B7H3 ADC) monotherapy in patients with previously treated advanced cervical cancer or platinum-resistant recurrent ovarian cancer: Outcomes by prior treatment
2026 · Ira Winer, Bo Gao, et al. · Gynecologic Oncology · 1
Abstract CT121: A phase 1/2a, multicenter, open-label, first in human study of a bispecific ADC targeting B7H3 and PDL1 (DB-1419) in advanced or metastatic solid tumors
2025 · Shun Lu, Charlotte Lemech, et al. · Cancer Research · 1
Abstract CT165: A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors
2024 · Ying Cheng, Aaron Lisberg, et al. · Cancer Research · 1
Abstract B130: DUP9, a novel ecteinascidin derivative, as a payload for antibody drug conjugates, exhibits promising preclinical efficacy
2025 · Shengchao Lin, Lei Yi, et al. · Molecular Cancer Therapeutics
Abstract B129: DUP5, a novel mRNA translation inhibitor as a payload for antibody drug conjugates, exhibits promising preclinical efficacy
2025 · Shengchao Lin, Bing Li, et al. · Molecular Cancer Therapeutics
Abstract CT168: A phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1310 (a HER3-targeting ADC) in patients with advanced/metastatic solid tumors
2024 · Aaron Lisberg, Shun Lu, et al. · Cancer Research
Abstract CT247: A Phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1303 in patients with advanced/metastatic solid tumors
2023 · Erika Hamilton, Jian Zhang, et al. · Cancer Research
Works count: 15
Citation count: 53
H-index: 4
I10-index: 2
Year
Topic
Type